Study Results from Hospital Britanico Buenos Aires Provide New Insights into Left Ventricular Hypertrophy (Agalsidase Alfa Long-term Effect On Left Ventricular Hypertrophy In Fabry Disease).

Předmět:	LEFT ventricular hypertrophy ANGIOKERATOMA corporis diffusum LIPID metabolism disorders LYSOSOMAL storage diseases X-linked genetic disorders
Zdroj:	Drug Week; 7/22/2024, p955-955, 1p
Abstrakt:	A study conducted at Hospital Britanico Buenos Aires in Argentina has provided new insights into left ventricular hypertrophy (LVH) in Fabry disease. Fabry disease is an X-linked lysosomal storage disorder that affects glycosphingolipid metabolism and often leads to cardiac involvement, specifically LVH. The study found that early initiation of enzyme replacement therapy (ERT) with agalsidase alfa can result in better cardiac outcomes, including stabilization of left ventricular mass index (LVMI). The research concluded that cardiac morphometric stability is a positive outcome of ERT. This study is one of the first of its kind in Argentina and aligns with previous literature on comparable Fabry disease populations. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu